Indeed, the DNMT inhibitors 5-azacitidine and 5-aza-2′deoxycytidine (decitabine) are effective agents in the treatment of patients with myelodysplastic syndromes and AML [13]. The gene discussed is DNMT1; the disease is acute myeloid leukemia.